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ORIGINAL ARTICLE
The mitochondrial encephalomyopathies are a
diverse group of disorders that result from the struc-
tural, biochemical or genetic derangement of mi-
tochondria.1 Mitochondrial encephalomyopathy,
lactic acidosis and stroke-like episodes (MELAS)
syndrome is one of the mitochondrial disorders
characterized by seizures, repeated stroke-like
episodes with focal neurologic deficits, recurrent
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Background/Purpose: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like
episodes) syndrome is often associated with A3243G point mutation of mitochondrial DNA (mtDNA).
We previously described a MELAS family characterized by harboring an additional ∼260 bp tandem dupli-
cation in the D-loop and a novel C3093G point mutation in the 16S rRNA gene of mtDNA in the proband.
We studied the clinical progression and fluctuation of mtDNA mutations in this Taiwanese MELAS family.
Methods: We followed up the clinical course in all members of this family (1 proband, her mother and 
3 sons) for 12 years. Mutations of mtDNA in serial muscle biopsies of the proband and blood samples
and hair follicles taken at different time points from the members of this family were analyzed.
Results: The proband developed repeated stroke-like episodes, chronic intestinal pseudo-obstruction, polyneu-
ropathy, progressive renal failure and dilated cardiomyopathy with heart failure. During the follow-up 
period, the mother and one of the siblings of the proband developed stroke-like episodes at age 62 and
12, respectively. There was no significant difference in the proportions of mtDNA with A3243G mutation
among five serial muscle biopsies of the proband. In one carrier (I-2), the proportion of A3243G mutated
mtDNA in blood cells was slightly increased with disease progression.
Conclusion: This study underlines the importance of early detection of extraneuromuscular symptoms in
the members of a family with MELAS syndrome by adequate follow-up. The age of onset of stroke-like episode
in MELAS syndrome may be as late as 62 years. We suggest that the manifestations of MELAS syndrome 
in this family might be associated with the additional ∼260 bp tandem duplication in the D-loop region
and the coexistence of C3093G mutation in the 16S rRNA gene with the A3243G mutation of mtDNA. 
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migraine-like headache, vomiting, cognitive im-
pairment with disease progression and ragged red
fibers on muscle biopsy.2,3 Most patients with
MELAS syndrome have been associated with the
A3243G mutation in the tRNALeu(UUR) gene.4,5
However, recent studies showed that the clinical
spectrum of the A3243G mutation is expanding
and other genetic mutations may also occur in
the affected tissues of patients with MELAS syn-
drome.6–9 These findings support the notion that
MELAS syndrome is a genetically heterogeneous
disease.
We described previously a unique MELAS
family characterized by harboring the A3243G
mutation and an additional ∼260 bp tandem du-
plication in the D-loop region of mitochondrial
DNA (mtDNA).10 Soon we also identified a novel
C3093G mtDNA mutation in the 16S rRNA gene
of mtDNA in the proband and her mother in this
MELAS family.11 Besides the manifestations of en-
cephalomyopathy, the proband presented with
diabetes mellitus and hyperthyroidism. Since the
proband harbored multiple mtDNA mutations,
study of the progression of the clinical pheno-
type of this family and the correlation between
clinical manifestations and mtDNA mutations
would be of particular interest.
Methods
Patients
The clinical symptoms of the proband of this fam-
ily with MELAS syndrome have been described
previously.10 She (patient II-2, Figure 1) had a
history of hyperthyroidism and received subtotal
thyroidectomy at age 26. She presented with dis-
orientation, psychiatric symptoms and epileptic
seizures at age 30. MELAS syndrome was diagnosed
based on the findings of multiple infarcts on brain
computed tomography (CT), elevated cerebral
spinal fluid lactate and ragged red fibers (RRF) on
muscle biopsy. Endocrinologic studies disclosed
diabetes mellitus and hyperthyroidism.10 Analysis
of mtDNA showed an AG transition at nucleo-
tide position (np) 3243 (A3243G mutation) in the
tRNALeu(UUR) gene and an additional ∼260 bp tan-
dem duplication in the D-loop region of mtDNA
in the three generations of the family.
In this family, subjects I-2, II-4, III-1, III-2 and
III-3 were all asymptomatic carriers at the time 
of the first stage of diagnosis. We have been con-
ducting follow-up studies on all of these family
members except II-4 for 12 years. Investigations
included physical examination, blood biochem-
istry, urinalysis, EKG, EEG, and ophthalmologic,
otologic and cardiologic examinations.
Medical imaging study
Serial single photon emission computed tomog-
raphy (SPECT) and magnetic resonance imaging
(MRI) scans and two positron emission tomog-
raphy (PET) scans of the brain were performed in
all maternal relatives of the proband and chrono-
logic changes were observed. A brain SPECT scan
was performed 60 minutes after intravenous in-
jection of 99mTc-HMPAO on a dual-head gamma
camera (Multispect II; Siemens, New York, NY,
USA) equipped with low-energy, high-resolution
collimators. Imaging was performed parallel to the
canthomeatal plane, starting below the level of
the cerebellum and extending to the vertex. Brain
MRI was performed on the 1.5-T superconducting
1
Family pedigree
1
2
2
I
II
III
3
1 2 3
4
Figure 1. Family pedigree of the patients with MELAS syn-
drome. The proband is indicated by an arrow. Solid symbols
show the members with full-blown MELAS syndrome.
Stripped symbols indicate oligosymptomatic relatives. Open
symbols show healthy relatives.
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system (GE Signa MRI; GE Healthcare) with a cir-
culatory polarizing head coil. The imaging stud-
ies included axial T1-weighted spin-echo (500/30/2
repetition time/echo time/excitations) and T2-
weighted fast spin-echo (4000/100/2) with echo
train length 8. Sections (5-mm thick) with 2.5-mm
interslice gaps, 24-cm field of view, and 256 ×
192 matrix were used for all scans. A PET scan-
ner (PC4096-15WB; Scanditronix Co., Uppsala,
Sweden) with eight ring detectors was used for
the study. The system produces 15 contiguous
slices, each in the thickness of 7 mm, and has 
a transaxial resolution of 5.6 mm full-width at
half maximum in the center of the field of view.
PET brain imaging was performed in the fasting
state 45 minutes after intravenous injection of
18F-fluorodeoxyglucose. Transmission scanning
for attenuation correction was conducted prior
to the emission study. Images were reconstructed
by standard filtered back projection using a Hann
filter with a filter width of 4.2 mm for 128 × 128
images.
Mitochondrial DNA mutation analysis
Muscle biopsies of the proband, done serially from
June 1993 to January 1997, were analyzed for
change in the proportion of mutated mtDNA with
the progression of disease. Blood samples and hair
follicles were collected annually from June 1994 to
February 1997. Total DNA was extracted from
skeletal muscle, blood leukocytes and hair follicles.
The target mtDNA fragment was amplified in a
100 µL reaction mixture containing 2–5 ng DNA,
200µM of the dNTPs, 20 pmol of each primer, 1.5
units of Taq DNA polymerase (Perkin-Elmer/Cetus,
Norwalk, CT, USA), 50 mM KCl, 1.5 mM MgCl2
and 10 mM Tris-HCl (pH 8.3). We performed
polymerase chain reaction (PCR) with 1 minute
of denaturation at 94°C, 1 minute of annealing 
at 56°C, and 1 minute of extension at 72°C for 30
cycles and then added 0.5 µCi of α-[33P]-dATP in
the last cycle in a Perkin-Elmer/Cetus DNA ther-
mal cycler. The region encompassing np 3058–
3343 of mtDNA was amplified by using a pair 
of primers, L3058 (np 3058–3092, 5’-TACGT-
GATCTGAGTTCAGACCGGAGTAATCCAGAT-3’)
and H3343 (np 3343–3324, 5’-TGGGTACAAT-
GAGGAGTAGG-3’), of human mtDNA. The
∼260 bp tandem duplication and A3243G and
C3093G mutations of mtDNA were analyzed as
described previously.10,11 The amplified DNA
fragments were digested with either Apa I (for the
A3243G mutation) or Dpn II (for the C3093G
mutation) and the restricted DNA fragments were
separated by electrophoresis on a 1.5% agarose
gel or 3% Nusieve plus 1% agarose gel at 100 volts
for 45 minutes. The relative proportion of the
mutated mtDNA was determined by scanning
densitometry and autoradiography of a Kodak 
X-ray film after exposure to the DNA bands in
the agarose gel.
Results
Table 1 presents the clinical manifestations and
paraclinical data of the proband and her mother
and three children. During the follow-up period,
the proband suffered from repeated stroke-like
episodes and progressive gait disturbance. Serial
brain SPECT revealed focal hyperperfusion during
the stroke-like episode (Figure 2A) and diffuse
hypoperfusion at the late stage (Figure 2B) of the
disease in the proband. Brain MRI showed multiple
infarcts and brain atrophy (Figure 2C). Episodes
of acute ileus (intestinal pseudo-obstruction) were
noted on plain abdominal X-ray (Figure 2D). Poly-
neuropathy and progressive renal failure with
proteinuria also developed subsequently. Thyroid
function test indicated sick euthyroid state. She
then developed congestive heart failure with acute
pulmonary edema and died of heart failure at
age 35.
Her mother (I-2) had been noted to have severe
sensorineural hearing impairment since the age
of 56. At age 62, she was sent to our emergency
room due to episodes of abdominal fullness and
generalized tonic-clonic seizure. Brain MRI re-
vealed acute cerebral infarcts in the left temporo-
parieto-occipital areas. Intestinal pseudo-obstruction,
chronic renal failure, recurrent stroke-like epi-
sodes and cortical blindness developed later. She
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Table 1. Clinical manifestations and paraclinical findings of the members in the MELAS family examined in this study
Family member I-2 II-2 III-1 III-2 III-3
Age (yr) at diagnosis 53 30 10 7 4
Sex F F M M M
Clinical manifestation
At diagnosis None Headache, episodic None None Lactic acidemia
vomiting, lactic 
acidosis, stroke-like 
episodes, NIDDM, 
hyperthyroidism
During follow-up SNHL, stroke-like Brain atrophy with Occasional Mild memory Mental retardation,
episodes, seizure, dementia, dilated headache, impairment, mild limb ataxia, 
myopathy, cardiomyopathy, nausea, occasional recurrent headache
vomiting, intestinal severe myopathy, vomiting, headache and vomiting, 
pseudo-obstruction, intestinal anorexia and and blurred stroke-like 
chronic pseudo-obstruction, blurred vision vision episodes, 
nephropathy polyneuropathy, seizures, SNHL, 
chronic nephropathy myopathy
EEG
At diagnosis Normal Generalized slowing Normal Normal Normal
During follow-up Focal slowing of No change Normal Normal Focal spike over 
cerebral activity over left posterior T-P 
left T-P-O regions areas and 
background 
slowing
SPECT
At diagnosis Normal Focal hyperperfusion Normal Normal Normal
during the stroke-like
episodes
During follow-up NA Diffuse hypoperfusion Normal Normal Hypoperfusion over
bil. occipital areas
MRI
At diagnosis Normal Old and new focal Normal Normal Normal
infarcts
During follow-up Multiple infarcts Multiple infarcts, Normal Normal Initially, high T2 
brain atrophy signal lesions in 
bil. PVWM, mild
cerebral and Ceb 
atrophy; Later, 
multiple infarcts
PET (during follow-up)
Regional glucose Normal (before NA Normal Normal Bil. F, bil. Ceb, 
metabolic deficit stroke-like right Th (before 
episodes) stroke-like 
episodes) and 
generalized areas 
at later stage
NIDDM = non-insulin dependent diabetes mellitus; SNHL = sensorineural hearing loss; NA = not available; bil. = bilateral; PVWM = periventricular white
matter; Ceb = cerebellum; Th = thalamus; F = frontal area; T-P-O = temporo-parieto-occipital area.
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died at home from an unknown cause at the age
of 64.
The serum lactate level had been high in pa-
tient III-3 since the first diagnosis when he was
about 4 years old. He presented with mental re-
tardation, recurrent headache, nausea and vom-
iting at age 6. Brain MRI at age 9 disclosed high
signal lesions in bilateral periventricular regions
and mild cerebral and cerebellar atrophy on T2-
weighted images. PET showed reduced cerebral
metabolic rate of glucose in bilateral frontal cor-
tex and cerebellum, and in the right thalamus. At
age 12, he was noted to develop severe headache,
seizure and right hemianopsia. Brain MRI revealed
cerebral infarcts in the left parietal and occipital
regions. At age 16, a PET scan revealed generalized
severe hypometabolism in the brain.
There were no ophthalmoplegia, heart con-
duction block or abnormal findings of oph-
thalmoscopy or echocardiography in all family
members during the follow-up period except
that audiometric measurement showed moder-
ate to severe hearing loss in III-3. None of these
family members developed diabetes mellitus or
hyperthyroidism.
Mitochondrial DNA mutation analysis
There was no significant difference in the propor-
tions of A3243G mutated mtDNA among four
serial muscle biopsies of the proband (Table 2).
Quantitative PCR analysis showed that the propor-
tion of mtDNA with the C3093G mutation was
approximately 51% in the muscle of the proband.
The levels of C3093G mutant mtDNA in blood
cells and hair follicles were 9% and 22% in the pro-
band and 4% and 10% in the patient I-2, respec-
tively (Table 3). However, the C3093G mutation
was not found in the blood cells and hair follicles
of the three sons of the proband. The C3093G mu-
tation of mtDNA was not found in the blood cells
or hair follicles of 23 normal healthy subjects.
The distribution of the A3243G and C3093G
mutant mtDNAs in the blood cells and hair folli-
cles of all maternal relatives and muscle biopsy
of the proband are summarized in Table 3. The
proportion of mtDNA with “+A3243G+C3093G”
A B
C D
Figure 2. Brain single photon emission computed 
tomography of the proband in the MELAS family: 
(A) decreased radioactivity in the left occipital area and
intense uptake in the right frontal region during the
stroke-like episode; (B) diffuse hypoperfusion at the  
late stage. (C) Brain T2-weighted magnetic resonance 
imaging shows multiple infarcts and diffuse brain 
atrophy. (D) Severe intestinal pseudo-obstruction on 
abdominal X-ray.
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genotype of the proband was higher than those
of the other three genotypes in muscle. In the mus-
cle of the proband, nucleotide sequence analysis
showed that the PCR-amplified mtDNA fragment
harbored both point mutations, which is consis-
tent with the findings of PCR-RFLP analysis.
Discussion
This family presented many features common 
to previously described MELAS pedigrees.5,12,13
Three members of the family (I-2, II-2, III-3) 
had the full-blown syndrome and the other
Table 2. Fluctuation of the proportions of the A3243G mutant mtDNA in various tissues of the MELAS family members*
Sample number†
I-2 II-2 III-1 III-2 III-3
B H B H M B H B H B H
1 4.6a 33.2a 41.5a 52.8a 79.6a 51.5a 45.5a 45.5a 43.5a 65.8a,b 74.2a
2 4.7a 33.3a 20.2b 54.3a 71.4b,d 47.9a 44.7a 42.9a 43.9a 65.4a,b 77.1a
3 6.6a,b 31.6a 41.0a 51.8a 74.7a,c 47.0a 43.6a 44.7a 45.4a 67.3a 77.5a
4 10.5b,c 31.6a 35.3a 54.8a 69.3d 38.1b 43.3a 38.6b 45.1a 54.2b,c 74.1a
5 13.5c NA 41.4a NA 73.6b,c 49.9a NA 45.1a NA 50.5c NA
*Statistical difference between the data of each tissue of any two of the five samples was determined by non-parametric independent analysis: presence of
the same superscripted letter indicates no significant difference (p > 0.05) between the two samples under comparison, and absence of similar super-
scripted letters represents a significant difference (p < 0.05) between the two samples under pair-wise comparison; †sample numbers 1 to 5 indicate the
mtDNAs of blood cells, hair follicles and muscle biopsies of the five family members (I-2, II-2, III-1, III-2 and III-3) collected at different time points.
B = blood; H = hair follicles; M = muscle; NA = not available.
Table 3. Proportions of the three mutant mtDNAs in different tissues of the five members of the MELAS family
Mitochondrial DNA mutation Tissues
Proportion of mutant mtDNA
I-2 II-2 III-1 III-2 III-3
A3243G mutation Muscle NA 82.0 NA NA NA
Blood 8.0 35.0 49.0 49.0 72.0
Hair follicles 36.0 55.0 45.0 47.0 83.0
C3093G mutation Muscle NA 51.0 NA NA NA
Blood 4.0 9.0 ND ND ND
Hair follicles 10.0 22.0 ND ND ND
260 bp tandem duplication Muscle NA 38.0 NA NA NA
Blood 0.8 1.6 0.8 0.4 1.6
Hair follicles 0.4 0.8 0.8 0.8 0.4
+A3243G+C3093G Blood ND ND NA NA NA
+A3243G−C3093G Blood 8.7 32.7 NA NA NA
−A3243G+C3093G Blood 4.6 7.4 NA NA NA
−A3243G−C3093G Blood 86.9 60.5 NA NA NA
+A3243G+C3093G Hair follicles ND ND NA NA NA
+A3243G−C3093G Hair follicles 35.1 47.8 NA NA NA
−A3243G+C3093G Hair follicles 9.7 24.8 NA NA NA
−A3243G−C3093G Hair follicles 55.2 27.4 NA NA NA
+A3243G+C3093G Muscle NA 41.8 NA NA NA
+A3243G−C3093G Muscle NA 32.2 NA NA NA
−A3243G+C3093G Muscle NA 10.2 NA NA NA
−A3243G−C3093G Muscle NA 15.8 NA NA NA
NA = not available; ND = not detectable.
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oligosymptomatic members (III-1, III-2) had rel-
atively mild features of the syndrome. During the
follow-up period, the proband developed pro-
gressive dementia, generalized muscle atrophy,
polyneuropathy, episodic subacute ileus, progres-
sive renal failure and dilated cardiomyopathy with
congestive heart failure. Patient III-3 developed re-
current headache and repeated stroke-like episodes
at the age of 12 and patient I-2 showed these
symptoms at the age of 62. Although diagnostic
criteria dictate that stroke-like episodes occur be-
fore age 40 in MELAS, it usually occurs before the
age of 30.12 To the best of our knowledge, late
onset of the stroke-like episode at age 62, as seen
in this patient, has never been reported before in
patients with MELAS syndrome.
Apart from the brain and muscle, several ex-
traneuromuscular organs were involved in the
family examined in this study. Many symptoms
of multisystemic involvement such as intestinal
pseudo-obstruction, chronic nephropathy, dilated
cardiomyopathy and sensorineural hearing im-
pairment developed gradually with disease progres-
sion. These findings are consistent with previous
reports.14–18 Mitochondrial encephalomyopathy
is a multisystemic disorder mainly involving skele-
tal muscle and the central nervous system, and
may also involve cardiac muscle, kidney and gas-
trointestinal tract.1,2,19 Mitochondrial defect can
affect virtually all organ systems.13 Our findings
suggest that attention should be paid to the devel-
opment of systemic manifestations and symptoms
that can be alleviated by earlier treatment.
The endocrinologic abnormalities in the pro-
band, including diabetes mellitus and hyper-
thyroidism have been described previously.10,11
However, these symptoms were not seen in other
family members. Although A3243G mutation of
mtDNA has been associated with diabetes,9,19,20
hyperthyroidism is rarely seen in MELAS patients.
Thyroid function test of the proband revealed
sick euthyroid state at the later stage, which may
be due to previous subtotal subthyroidectomy.
Whether the hyperthyroidism observed in the
proband is related to MELAS syndrome needs
further investigation.
There are some reports of long-term studies
of serial imaging in MELAS patients.21,22 In the
proband, brain CT/MRI showed progression of
infarcts. The infarction did not conform to defi-
nite vascular territories and tended to fluctuate.
Focal hyperperfusion on SPECT was observed dur-
ing acute stroke and diffuse hypoperfusion during
follow-up. This is consistent with the findings of
previous studies.22,23 EEG and brain SPECT did
not reveal any abnormalities in asymptomatic car-
riers before the development of stroke-like episodes
during follow-up. MRI of the brain in patient 
III-3 before the development of stroke-like episodes
showed hyperintense lesions on T2-weighted im-
ages in bilateral periventricular regions and mild
cerebral and cerebellar atrophy. These MRI find-
ings are similar to those reported by previous
studies.21,24 The initial PET finding was abnor-
mal when subject III-3 was clinically asympto-
matic, which suggests that PET is a sensitive tool
to evaluate the cerebral metabolism in MELAS
patients. Sano et al25 also reported a patient with
MELAS syndrome, in whom PET study demon-
strated that the regional metabolic rate of oxygen
was remarkably decreased, while regional meta-
bolic rate of glucose was not decreased. We be-
lieve that the regional glucose metabolic deficit
is truly pathologic and significant. To determine
whether these abnormalities are related to stroke-
like episodes in MELAS, further study including
measurement of oxygen consumption is needed.
Disease progression in patients with mitochon-
drial disorders is thought to be related to the pro-
portion of mutant mtDNA. Larsson et al26 found
an increase with time of the mutated mtDNA in
muscle in two cases and this increase paralleled the
progression of the disease. Another study reported
that a decline in the level of A3243G mutant
mtDNA is associated with clinical and histo-
chemical improvement.27 The results obtained in
this study (Table 2) do not show significant change
in the proportion of mutated mtDNA in the mus-
cle tissues of the proband during the progression
of the disease. This suggests that this pathogenic
mutation of mtDNA was distributed in a stable
manner in affected tissues since the early stage 
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of embryonic development. In patient I-2, the
proportion of A3243G mutated mtDNA in blood
cells slightly increased during disease progres-
sion. This finding is consistent with the report of
a previous study.26
The results compiled in Table 3 show that the
proportion of the A3243G mutant mtDNA of
the blood cells and hair follicles of subjects III-1,
III-2 and III-3 were very high or even higher than
those of the proband. However, C3093G mutant
mtDNA could not be detected in the blood cells
and hair follicles of the three matrilineal members
of this family. It is apparent that the C3093G
mutant mtDNA was completely selected out in
just one generation.
The mode of segregation and transmission 
of mtDNA with the C3093G mutation in this
family suggest that the C3093G mutant mtDNA
is segregated with tissue specificity and with rapid
and extreme genetic shift in one generation of this
family. The mechanisms of fluctuation or fixa-
tion of the mutant mtDNA in the maternal line-
ages remain unclear. These findings suggest that
the C3093G mutation of mtDNA first occurred at
low abundance in the proband’s mother in this
family and that the proband inherited a higher
proportion of the C3093G mutant mtDNA from
her mother and widely spread in the muscle tissue
and manifested more severe clinical symptoms.
Although more extensive studies are required be-
fore a solid conclusion can be made, our findings
suggest that the C3093G mutant mtDNA had been
more rapidly amplified in the affected tissues of
the proband of this MELAS family and was then
actively and completely selected out in her three
sons. The origin of the triple mutations in the
mtDNA of the proband in this family could not
be traced. Whether the A3243G mutation predis-
poses to the other two mutations in the mito-
chondrial genome remains unclear. There are some
previous reports of coexistence of two mutations in
patients with mitochondrial diseases. Ohno et al28
found a MELAS and Kearns-Sayre syndrome co-
mutation in a patient with myopathy and au-
toimmune polyendocrinopathy. They suggested
that the A3243G mutation probably predisposed
to the large-scale mtDNA deletion. Bidooki et al29
documented a patient with mitochondrial encep-
halopathy who harbored two mutations at differ-
ent tRNA genes in mtDNA. The contribution of
the two mutations to the phenotypic expression
was not determined. Arenas et al30 also reported
a double mutation in the tRNALys gene, which was
associated with myoclonus epilepsy with ragged
red fibers (MERRF) syndrome.
In conclusion, this family is rather interesting
because the proband and her maternal relatives
harbored several pathologic mutations in mtDNA
at widely varied levels. Many pathologic mani-
festations of the affected organs developed grad-
ually during the follow-up study. The very late
onset of stroke-like episodes in patient I-2 is ex-
tremely rare for MELAS syndrome. The manifes-
tations of MELAS syndrome in this family might
be associated with the additional ∼260 bp tandem
duplication in the D-loop region and the coexis-
tence of C3093G mutation in the 16S rRNA gene
of mtDNA.
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